Supernus Pharmaceuticals, Inc.
SUPN
$56.50
$0.821.47%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 10.43% | -13.97% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.43% | -13.97% | |||
| Cost of Revenue | 6.75% | -39.60% | |||
| Gross Profit | 10.86% | -9.46% | |||
| SG&A Expenses | 0.22% | 15.60% | |||
| Depreciation & Amortization | 5.22% | 8.45% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.60% | 1.44% | |||
| Operating Income | 259.25% | -135.77% | |||
| Income Before Tax | 385.87% | -122.10% | |||
| Income Tax Expenses | -197.23% | -45.76% | |||
| Earnings from Continuing Operations | 290.23% | -177.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 290.23% | -177.16% | |||
| EBIT | 259.25% | -135.77% | |||
| EBITDA | 142.77% | -65.14% | |||
| EPS Basic | 289.70% | -176.59% | |||
| Normalized Basic EPS | 706.94% | -110.42% | |||
| EPS Diluted | 288.95% | -178.20% | |||
| Normalized Diluted EPS | 700.35% | -110.61% | |||
| Average Basic Shares Outstanding | 0.29% | 0.72% | |||
| Average Diluted Shares Outstanding | 1.39% | -1.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||